Welcome to our dedicated page for Marijuana news (Ticker: MAJI), a resource for investors and traders seeking the latest updates and insights on Marijuana stock.
Marijuana Inc. (MAJI), operating as Exousia Pro, Inc., is a clinical-stage biotechnology leader developing plant-based exosome therapies for skincare, oncology, and dental applications. This page provides investors and industry observers with timely updates on the company’s scientific advancements, regulatory milestones, and strategic partnerships.
Access official press releases and curated news covering MAJI’s proprietary exosome technologies, including innovations in targeted drug delivery and cosmeceutical products. Key updates include clinical trial progress, manufacturing developments, and market expansion initiatives such as the integration of Exousia AI’s research capabilities.
Content spans earnings reports, product launches, intellectual property updates, and partnership announcements. Bookmark this page for direct access to verified information supporting informed analysis of MAJI’s evolving role in the biotech sector.
Exousia Pro (OTC PINK:MAJI) has shared significant findings regarding their Glioblastoma (GBM) study. Chief Science Officer Dr. Marvin Hausman revealed in a Spaces interview that published research demonstrates the effectiveness of NANOG Expression therapy in treating GBM cells.
The research showed that while temozolomide (TMZ) alone at maximum concentration eliminated less than 20% of GBM cells, combining TMZ with shRNA targeting NANOG or OCT4 significantly increased cell death rates. This combination therapy proved particularly effective at reducing the resistance of Cancer stem cells in Glioblastoma.
Exousia Pro (OTCPINK:MAJI), a clinical-stage biotech company, has announced the formation of new subdivisions to expand its plant-based exosome technology beyond cancer therapies. The company is establishing three wholly owned subsidiaries:
- Biotech: Focused on cancer therapies using exosomes
- Cosmeceutical: Targeting the skincare industry with two studies in progress
- Nutraceutical: Developing exosome-enhanced anti-aging supplements, IV therapies, tinctures, and peptides in a market valued at $73-85 billion (2024/2025)
The company plans to enter these markets through joint ventures with established companies, enhancing their products with plant-based exosomes. Exousia Pro is also in final negotiations for a licensing deal that would enable entry into four additional markets.
Marijuana Inc (OTCPINK:MAJI), operating as Exousia Pro, has received an order to deliver 500 billion dried exosomes for a trade show demonstration. The exosomes will be divided into 100 samples of 5 billion each and mixed into a cream to showcase a new product line.
The company is working with a partner serving over 300 clients (MedSpas and Dermatologist offices) who plans to transition from mammalian to plant-based exosomes in their products. The partner currently sells 1,500 bottles of hair serum monthly and aims to expand their product line using Exousia's mushroom exosomes.
Each 5 billion exosome order sells for $5.00 with a $2.00 manufacturing cost, resulting in a 60% profit margin. Exousia Pro claims to be the only company capable of producing dried plant-based exosomes, offering extended shelf life for medical and cosmeceutical applications.
Marijuana Inc. (OTC PINK:MAJI), operating as Exousia Pro, Inc., has received feedback from FINRA regarding its pending name change application. The clinical-stage biotech company, which focuses on exosome-based treatments for cancer and other diseases, has submitted required documentation including Board minutes and Articles of Amendment to the State of Florida. To facilitate the parent company's name change, the subsidiary's name was changed from Exousia Pro, Inc. to Exousia AI, Inc. According to company president Matthew Dwyer, FINRA's response within the first 30 days of filing indicates positive progress in the process.
Marijuana Inc. (OTC PINK:MAJI), operating as Exousia Pro, has appointed Matthew Dwyer as its new President. Dwyer brings 37 years of market experience, specializing in OTC markets and SEC procedures. He currently co-owns a brokerage firm and has maintained a clean regulatory record throughout his career.
Dwyer's appointment comes with a performance-based compensation package, including shares and cash bonus upon completing key objectives: company audit, advisory board creation, SEC share registration, OTCQB uplisting, revenue generation through organic growth and acquisitions, and securing investment banking relationships.
The company, a clinical-stage biotech focusing on exosome treatments for cancer and other conditions, aims to advance its glioblastoma therapeutic and commercialize exosome technology. CEO Mike Sheikh emphasized Dwyer's regulatory expertise as important for achieving fully reporting status while avoiding toxic financing structures.
Exousia Pro (OTC PINK:MAJI) has provided an update on its FDA Orphan Drug application for its Glioblastoma treatment using exosomes. The FDA has requested additional information from an ongoing UCF study, expected to be completed by mid-May 2025. The company reports positive preliminary anecdotal data, noting that certain animal cohorts are maintaining weight, indicating good health.
If granted, the Orphan Drug designation would provide significant benefits including:
- Seven-year marketing exclusivity
- Tax credits for qualified clinical testing
- PDUFA application fee waivers
- FDA development assistance
- Eligibility for research grants
The company's combination therapy aims to treat both methylated and unmethylated glioblastoma patients who are resistant to standard chemotherapy. The ongoing trial uses humanized mice and human donor glioblastoma, setting a higher standard than typical preclinical trials.
Marijuana Inc. (OTC PINK:MAJI), operating as Exousia Pro, has officially begun production of mushroom-based exosomes at its Orlando lab. The company is utilizing licensed intellectual property from Progenycite to extract high-quality exosomes from mushrooms for skincare and wellness applications.
The company's product line will offer various exosome formulations targeting specific skincare needs, featuring benefits such as:
- Antioxidant effects from polyphenols and selenium
- Moisturizing properties from beta-glucan
- Anti-inflammatory effects from Vitamin B Complex
- Skin renewal properties from Vitamin D₂
- Brightening and anti-aging benefits from selenium, polyphenols, and niacin
CEO Michael Sheikh reported strong interest from multiple distributors and formulators, with sample production marking their first commercialization milestone. The company expects significant business growth and revenue recognition in the coming quarter.
Exousia Pro (OTCPINK:MAJI) has successfully renegotiated its license agreement with Progenicyte of Japan, reducing the licensing fee from 50% to 30% equity position. The agreement grants worldwide licensing rights to Progenicyte's Exosome DNA loading patent and future exosome technologies.
Under the new terms, Exousia Pro will pay Progenicyte a monthly operating fee of $16,667. The patent has been filed in Japan, US, Canada, Europe, and China. Progenicyte will continue developing new exosome uses and devices exclusively licensed to Exousia Pro.
The company views this technology as important for scaling exosome manufacturing, noting that among approximately 10,000 active clinical trials, only 10 currently use exosomes. Exousia Pro aims to demonstrate the technology's potential in Glioblastoma treatment and believes it could compete with the monoclonal antibodies market, which represents over 30% of pharmaceutical sales.
Marijuana Inc. (OTCPINK: MAJI) has acquired 100% of Exousia AI in a cash and stock transaction, issuing 47 million restricted shares to Ludwig Enterprises with specific lock-up features tied to NASDAQ uplisting. The deal includes assuming liabilities under $75,000 and a $100,000 note.
The acquisition brings worldwide licensed technology for plant-based and human-derived exosomes, including ongoing studies for Glioblastoma treatment and planned studies in dermatology and dental markets. The company will manufacture and sell exosomes for nutraceutical and dermatology markets, targeting the rapidly growing cosmeceuticals sector.
The exosome skincare market is projected to grow from $310 million in 2025 to $633 million in 2033, with a 10% compound annual growth rate. A 30-day treatment currently sells for $400 per vial. The company plans to expand its oncology studies and potentially license its technology to drug manufacturers for enhanced chemotherapy treatments.
